Nachrichten zur Inventiva S.A. Aktie

Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024

Daix (France), Long Island City (New York, United States), October 21, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA)…

Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants

Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva”…

Inventiva announces a €20.1 million issuance of royalty certificates

Daix (France), Long Island City (New York, United States), July 18, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva”…

Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position

Daix (France), Long Island City (New York, United States), July 5, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or…

Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor

Daix (France), Long Island City (New York, United States), May 13, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a…

Inventiva S.A. (IVA) Q4 2023 Earnings Call Transcript

…

Inventiva: share price falls, phase III recruitment suspended

Inventiva fell sharply on the stock market on Friday morning, following the announcement of the suspension of recruitment for its…

Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3

Daix (France), Long Island City (New York, United States), February 15, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the…

Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program

…

Inventiva reports 9M results

…

Inventiva S.A. (IVA) Q2 2023 Earnings Analyst Call Transcript

…

Inventiva reports its 2023 first-half financial results and provides a corporate update

Daix (France), Long Island City (New York, United States), September 28, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the…

Inventiva and Hepalys Pharma to develop and commercialize Lanifibranor in Japan and South Korea

…

Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea

…

Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update

...…

Form 6-K Inventiva S.A. For: Jul 27

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update

...…

Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association

Daix (France), Long Island City (New York, United States), June 24, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a…

Where Inventiva Stands With Analysts

Latest Ratings for IVA DateFirmActionFromTo Nov 2021HC Wainwright & Co.MaintainsBuy Sep 2021HC Wainwright & Co.MaintainsBuy Mar 2021Societe GeneraleDowngradesBuySell …

Inventiva jumps 25% after mid-stage data for NASH candidate

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Inventiva, Gossamer top healthcare gainers; IO Biotech, agilon among losers

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Pre-market Movers: EAST, CNVS, DRIO, AGRX, Inventiva.

ROMANEL-SUR-MORGES (dpa-AFX) - The following are some of the stocks making big moves in Wednesdays pre-market trading (as of 07.05…

Inventiva ADRs Soar 30% Post-Market Following Positive Results From Phase 2 Study

Inventiva ADRs Soar 30% Post-Market Following Positive Results From Phase 2 Study...…

Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD

Daix (France), Long Island City (New York, United States), June 13, 2022 –Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage…

Inventiva announces five scientific presentations at the EASL International Liver Congress™ 2023

Daix (France), Long Island City (New York, United States), June 7, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage…

Form 6-K Inventiva S.A. For: May 26

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China

...…

Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis

...…

dpa-AFX ProFeed